Federal Circuit Invalidates Cytiva Antibody Isolation Patents in Favor of JSR Corp.

In a significant legal development, the Federal Circuit issued a precedential opinion determining that all claims contested by JSR Corp. in three Cytiva Bioprocess antibody isolation patents are invalid due to obviousness. This decision supports the Patent Trial and Appeal Board’s (PTAB) earlier verdict, which had invalidated several claims, while concurrently overturning the board’s decision to uphold others. This ruling marks an important legal victory for JSR Corp., given the complex landscape of antibody isolation patents, which are critical in the bioprocessing industry. For further details, the original article on this case is available on Law360.